1.000000
0.000000
0.000000
0.000000
1.000000
0.000000
0.000000
0.000000
1.000000
0.00000
0.00000
0.00000
SER A 2 AND SER B 7 OF EACH MODEL ARE D-SERINE.
CYS A 4 AND VAL A 5 OF EACH MODEL ARE METHYLATED. CYS B 9 AND VAL B 10 OF EACH MODEL ARE METHYLATED.
Addess, K.J.
Feigon, J.
http://mmcif.pdb.org/dictionaries/ascii/mmcif_pdbx.dic
1
90.00
90.00
90.00
1.000
1.000
1.000
C3 H7 N O2
89.093
y
ALANINE
L-peptide linking
C10 H14 N5 O6 P
331.222
y
2'-DEOXYADENOSINE-5'-MONOPHOSPHATE
DNA linking
C9 H14 N3 O7 P
307.197
y
2'-DEOXYCYTIDINE-5'-MONOPHOSPHATE
DNA linking
C10 H14 N5 O7 P
347.221
y
2'-DEOXYGUANOSINE-5'-MONOPHOSPHATE
DNA linking
C3 H7 N O3
105.093
D-SERINE
D-peptide linking
C10 H15 N2 O8 P
322.208
y
THYMIDINE-5'-MONOPHOSPHATE
DNA linking
C6 H13 N O2
131.173
n
N-METHYLVALINE
L-peptide linking
C4 H9 N O2 S
135.185
N-METHYLCYSTEINE
L-peptide linking
C9 H6 N2 O2
174.156
2-CARBOXYQUINOXALINE
non-polymer
US
Biochemistry
BICHAW
0033
0006-2960
33
12386
10.1021/BI00207A005
7918461
Sequence Specificity of Quinoxaline Antibiotics. 1. Solution Structure of a 1:1 Complex between Triostin a and [D(Gacgtc)]2 and Comparison with the Solution Structure of the [N-Mecys3,N-Mecys7]Tandem-[D(Gatatc)]2 Complex.
1994
US
Biochemistry
BICHAW
0033
0006-2960
32
2498
10.1021/BI00061A006
8448108
Solution Structure of a Complex between [N-Mecys3,N-Mecys7]Tandem and [D(Gatatc)]2
1993
1.000000
0.000000
0.000000
0.000000
1.000000
0.000000
0.000000
0.000000
1.000000
0.00000
0.00000
0.00000
794.982
TRIOSTIN A
1
syn
polymer
1809.217
DNA (5'-D(*GP*AP*CP*GP*TP*C)-3')
2
syn
polymer
174.156
2-CARBOXYQUINOXALINE
2
syn
non-polymer
DEOXYRIBONUCLEIC ACID
no
yes
(DSN)A(NCY)(MVA)(DSN)A(NCY)(MVA)
SAXVSAXV
A
polypeptide(L)
no
no
(DG)(DA)(DC)(DG)(DT)(DC)
GACGTC
C,D
polydeoxyribonucleotide
n
n
n
n
n
n
n
n
n
n
n
n
n
n
-14.370
1
19
C
11
D
22
-0.495
C_DG11:DC22_D
1
-3.264
-0.890
0.397
-0.526
9.008
1
20
C
12
D
21
4.495
C_DA12:DT21_D
2
8.738
-0.015
0.872
-0.315
-24.430
1
19
C
13
D
20
-5.477
C_DC13:DG20_D
3
-0.995
-0.057
0.983
-0.287
25.113
1
19
C
14
D
19
-6.480
C_DG14:DC19_D
4
-1.344
0.112
0.844
-0.214
-11.378
1
20
C
15
D
18
8.624
C_DT15:DA18_D
5
7.795
0.116
1.196
-0.481
-2.720
1
19
C
16
D
17
-11.682
C_DC16:DG17_D
6
-17.550
0.136
1.241
-0.607
2.591
44.367
C
C
11
12
-5.373
D
D
22
21
2.653
-4.047
0.508
-0.035
CC_DG11DA12:DT21DC22_DD
1
-4.114
5.462
44.009
0.256
-0.980
7.114
27.116
C
C
12
13
6.445
D
D
21
20
7.338
2.955
0.547
0.688
CC_DA12DC13:DG20DT21_DD
2
9.392
-20.484
25.296
-0.240
4.263
1.466
2.739
C
C
13
14
70.488
D
D
20
19
2.301
2.581
-0.376
0.733
CC_DC13DG14:DC19DG20_DD
3
-0.055
1.498
0.914
-40.350
6.690
3.120
42.825
C
C
15
16
-5.926
D
D
18
17
2.987
-4.314
-1.675
-0.102
CC_DT15DC16:DG17DA18_DD
4
-3.985
5.474
42.439
0.263
1.921
pdbx_database_status
pdbx_struct_assembly
pdbx_validate_polymer_linkage
repository
Initial release
Version format compliance
Version format compliance
Atomic model
Database references
Derived calculations
Non-polymer description
Structure summary
Other
Advisory
Derived calculations
Other
1
0
1995-02-07
1
1
2011-06-14
1
2
2011-07-13
1
3
2011-07-27
1
4
2013-02-27
1
5
2017-11-01
_pdbx_database_status.process_site
_pdbx_struct_assembly.method_details
SOLUTION STRUCTURE OF D(ACACGTGT) COMPLEXED WITH QUINOMYCIN UK-6305
CRYSTAL STRUCTURE OF D(GCGTACG) COMPLEXED WITH ECHINOMYCIN - SPACE GROUP P6322
CRYSTAL STRUCTURE OF D(GCGTACGC) COMPLEXED WITH TRIOSIN A
CRYSTAL STRUCTURE OF D(GCGTACGC) COMPLEXED WITH ECHINOMYCIN - SPACE GROUP P632
CRYSTAL STRUCTURE OF D(ACGTACGT) COMPLEXED WITH ECHINOMYCIN - SPACE GROUP P632
CRYSTAL STRUCTURE OF D(CGTACG) COMPLEXED WITH ECHINOMYCIN - SPACE GROUP C21
CRYSTAL STRUCTURE OF D(ACGTACGT) COMPLEXED WITH ECHINOMYCIN - SPACE GROUP P42212
SOLUTION STRUCTURE OF D(GATATC) COMPLEXED WITH A MODIFIED TRIOSTIN A AT POSITIONS 4 AND 8
CRYSTAL STRUCTURE OF D(ACGTACGT) COMPLEXED WITH ECHINOMYCIN - SPACE GROUP P41212
Y
BNL
1994-08-10
REL
QUI
2-CARBOXYQUINOXALINE
1931
STREPTOMYCINEAE
sample
TRIOSTIN IS A BICYCLIC OCTADEPSIPEPTIDE, A MEMBER
OF THE QUINOXALINE CLASS OF ANTIBIOTICS.
HERE, TRIOSTIN IS REPRESENTED BY GROUPING TOGETHER THE
SEQUENCE (SEQRES) AND THE TWO LIGANDS (HET) QUI
Anticancer
TRIOSTIN IS A BICYCLIC OCTADEPSIPEPTIDE.
BICYCLIZATION IS ACHIEVED BY LINKING THE N- AND
THE C- TERMINI, AND A DISULPHIDE BOND BETWEEN
RESIDUES 3 AND 7.
THE TWO QUINOXALINE CHROMOPHORES ARE LINKED
TO THE D-SERINE RESIDUES, RESIDUES 1 AND 5.
TRIOSTIN A
Cyclic depsipeptide
TRIOSTIN A CONTAINS TWO PLANAR AROMATIC QUINOXALINE RINGS THAT ARE COVALENTLY ATTACHED TO A CYCLIC OCTADEPSIPEPTIDE RING REPRESENTED BY CHAINS A AND B IN THIS ENTRY. THERE IS A DISULFIDE BRIDGE LINKING CYS A 4 TO CYS B 9. BOTH CYS AND VAL RESIDUES CONTAIN METHYLATED AMIDE NITROGENS; THE TWO D-SER RESIDUES ARE AMIDE BONDED TO THE TWO QUINOXALINE RINGS.
5
NUMBER OF ATOMS PRESENT IN ENTRY. NUMBER OF PROTEIN ATOMS 328 NUMBER OF NUCLEIC ACID ATOMS 48 NUMBER OF SOLVENT ATOMS 240 NUMBER OF HETEROGEN ATOMS 40 AVERAGE PAIRWISE RMSD BOND DISTANCES FOR HEAVY ATOM POSITIONS FOR 5 STRUCTURES: 1.37 ANGSTROMS.
DISTANCE GEOMETRY, MOLECULAR DYNAMICS
BRUNGER
refinement
X-PLOR
QUI
0
3
QUI
QUI
0
A
QUI
9
3
QUI
QUI
9
A
DSN
1
n
1
DSN
1
A
ALA
2
n
2
ALA
2
A
NCY
3
n
3
NCY
3
A
MVA
4
n
4
MVA
4
A
DSN
5
n
5
DSN
5
A
ALA
6
n
6
ALA
6
A
NCY
7
n
7
NCY
7
A
MVA
8
n
8
MVA
8
A
DG
11
n
1
DG
11
C
DA
12
n
2
DA
12
C
DC
13
n
3
DC
13
C
DG
14
n
4
DG
14
C
DT
15
n
5
DT
15
C
DC
16
n
6
DC
16
C
DG
17
n
1
DG
17
D
DA
18
n
2
DA
18
D
DC
19
n
3
DC
19
D
DG
20
n
4
DG
20
D
DT
21
n
5
DT
21
D
DC
22
n
6
DC
22
D
software_defined_assembly
PISA
3
trimeric
2080
-3
2840
1.0000000000
0.0000000000
0.0000000000
0.0000000000
1.0000000000
0.0000000000
0.0000000000
0.0000000000
1.0000000000
1_555
x,y,z
identity operation
0.0000000000
0.0000000000
0.0000000000
4
A
A
C
N
MVA
DSN
4
5
2.81
5
A
A
C
N
MVA
DSN
4
5
2.88
1
1.94
0.30
108.30
110.24
C
C
C
O4'
C1'
N9
DG
DG
DG
11
11
11
N
1
3.28
0.50
113.10
116.38
C
C
C
N7
C8
N9
DG
DG
DG
11
11
11
N
1
-6.21
1.00
110.10
103.89
C
C
C
C1'
O4'
C4'
DC
DC
DC
13
13
13
N
1
3.77
0.60
118.90
122.67
C
C
C
N1
C2
O2
DC
DC
DC
13
13
13
N
1
-5.50
0.80
105.90
100.40
C
C
C
O4'
C1'
C2'
DG
DG
DG
14
14
14
N
1
3.23
0.50
113.10
116.33
C
C
C
N7
C8
N9
DG
DG
DG
14
14
14
N
1
-6.50
1.00
110.10
103.60
D
D
D
C1'
O4'
C4'
DG
DG
DG
17
17
17
N
1
3.26
0.50
113.10
116.36
D
D
D
N7
C8
N9
DG
DG
DG
17
17
17
N
1
-6.82
1.00
110.10
103.28
D
D
D
C1'
O4'
C4'
DC
DC
DC
19
19
19
N
1
2.72
0.30
108.30
111.02
D
D
D
O4'
C1'
N1
DC
DC
DC
19
19
19
N
1
3.73
0.60
118.90
122.63
D
D
D
N1
C2
O2
DC
DC
DC
19
19
19
N
1
3.14
0.50
113.10
116.24
D
D
D
N7
C8
N9
DG
DG
DG
20
20
20
N
1
-4.88
0.80
105.90
101.02
D
D
D
O4'
C1'
C2'
DT
DT
DT
21
21
21
N
1
2.77
0.30
108.30
111.07
D
D
D
O4'
C1'
N1
DC
DC
DC
22
22
22
N
2
-5.31
0.80
105.90
100.59
C
C
C
O4'
C1'
C2'
DG
DG
DG
11
11
11
N
2
4.53
0.30
108.30
112.83
C
C
C
O4'
C1'
N9
DG
DG
DG
11
11
11
N
2
3.07
0.50
113.10
116.17
C
C
C
N7
C8
N9
DG
DG
DG
11
11
11
N
2
1.83
0.30
108.30
110.13
C
C
C
O4'
C1'
N1
DC
DC
DC
13
13
13
N
2
-5.86
0.80
105.90
100.04
C
C
C
O4'
C1'
C2'
DG
DG
DG
14
14
14
N
2
3.91
0.30
108.30
112.21
C
C
C
O4'
C1'
N9
DG
DG
DG
14
14
14
N
2
3.27
0.50
113.10
116.37
C
C
C
N7
C8
N9
DG
DG
DG
14
14
14
N
2
3.36
0.30
108.30
111.66
C
C
C
O4'
C1'
N1
DC
DC
DC
16
16
16
N
2
3.47
0.50
113.10
116.57
D
D
D
N7
C8
N9
DG
DG
DG
17
17
17
N
2
-6.18
1.00
110.10
103.92
D
D
D
C1'
O4'
C4'
DG
DG
DG
20
20
20
N
2
-6.79
0.80
105.90
99.11
D
D
D
O4'
C1'
C2'
DG
DG
DG
20
20
20
N
2
4.38
0.30
108.30
112.68
D
D
D
O4'
C1'
N9
DG
DG
DG
20
20
20
N
2
3.27
0.50
113.10
116.37
D
D
D
N7
C8
N9
DG
DG
DG
20
20
20
N
3
2.01
0.30
108.30
110.31
C
C
C
O4'
C1'
N9
DG
DG
DG
11
11
11
N
3
3.35
0.50
113.10
116.45
C
C
C
N7
C8
N9
DG
DG
DG
11
11
11
N
3
2.55
0.30
108.30
110.85
C
C
C
O4'
C1'
N9
DA
DA
DA
12
12
12
N
3
3.50
0.30
108.30
111.80
C
C
C
O4'
C1'
N1
DC
DC
DC
13
13
13
N
3
2.16
0.30
108.30
110.46
C
C
C
O4'
C1'
N9
DG
DG
DG
14
14
14
N
3
3.19
0.50
113.10
116.29
C
C
C
N7
C8
N9
DG
DG
DG
14
14
14
N
3
-6.75
0.80
105.90
99.15
C
C
C
O4'
C1'
C2'
DT
DT
DT
15
15
15
N
3
3.11
0.30
108.30
111.41
C
C
C
O4'
C1'
N1
DC
DC
DC
16
16
16
N
3
3.35
0.50
113.10
116.45
D
D
D
N7
C8
N9
DG
DG
DG
17
17
17
N
3
9.22
1.20
119.70
128.92
D
D
D
C3'
O3'
P
DG
DG
DA
17
17
18
Y
3
-4.91
0.80
105.90
100.99
D
D
D
O4'
C1'
C2'
DA
DA
DA
18
18
18
N
3
-4.57
0.70
102.20
97.63
D
D
D
C4'
C3'
C2'
DC
DC
DC
19
19
19
N
3
4.04
0.30
108.30
112.34
D
D
D
O4'
C1'
N1
DC
DC
DC
19
19
19
N
3
-5.54
0.80
105.90
100.36
D
D
D
O4'
C1'
C2'
DG
DG
DG
20
20
20
N
3
3.63
0.30
108.30
111.93
D
D
D
O4'
C1'
N9
DG
DG
DG
20
20
20
N
3
3.23
0.50
113.10
116.33
D
D
D
N7
C8
N9
DG
DG
DG
20
20
20
N
3
4.11
0.30
108.30
112.41
D
D
D
O4'
C1'
N1
DC
DC
DC
22
22
22
N
4
-5.38
0.80
105.90
100.52
C
C
C
O4'
C1'
C2'
DG
DG
DG
11
11
11
N
4
4.41
0.30
108.30
112.71
C
C
C
O4'
C1'
N9
DG
DG
DG
11
11
11
N
4
3.30
0.50
113.10
116.40
C
C
C
N7
C8
N9
DG
DG
DG
11
11
11
N
4
-5.17
0.70
102.20
97.03
C
C
C
C4'
C3'
C2'
DC
DC
DC
13
13
13
N
4
5.15
0.30
108.30
113.45
C
C
C
O4'
C1'
N1
DC
DC
DC
13
13
13
N
4
-5.38
0.80
105.90
100.52
C
C
C
O4'
C1'
C2'
DG
DG
DG
14
14
14
N
4
3.29
0.50
113.10
116.39
C
C
C
N7
C8
N9
DG
DG
DG
14
14
14
N
4
-4.71
0.70
102.20
97.49
C
C
C
C4'
C3'
C2'
DC
DC
DC
16
16
16
N
4
5.70
0.30
108.30
114.00
C
C
C
O4'
C1'
N1
DC
DC
DC
16
16
16
N
4
2.85
0.30
108.30
111.15
D
D
D
O4'
C1'
N9
DG
DG
DG
17
17
17
N
4
3.54
0.50
113.10
116.64
D
D
D
N7
C8
N9
DG
DG
DG
17
17
17
N
4
4.24
0.30
108.30
112.54
D
D
D
O4'
C1'
N9
DA
DA
DA
18
18
18
N
4
2.03
0.30
108.30
110.33
D
D
D
O4'
C1'
N1
DC
DC
DC
19
19
19
N
4
-5.74
0.80
105.90
100.16
D
D
D
O4'
C1'
C2'
DG
DG
DG
20
20
20
N
4
3.67
0.30
108.30
111.97
D
D
D
O4'
C1'
N9
DG
DG
DG
20
20
20
N
4
3.38
0.50
113.10
116.48
D
D
D
N7
C8
N9
DG
DG
DG
20
20
20
N
5
3.29
0.50
113.10
116.39
C
C
C
N7
C8
N9
DG
DG
DG
11
11
11
N
5
3.58
0.30
108.30
111.88
C
C
C
O4'
C1'
N1
DC
DC
DC
13
13
13
N
5
-5.23
0.80
105.90
100.67
C
C
C
O4'
C1'
C2'
DG
DG
DG
14
14
14
N
5
2.87
0.30
108.30
111.17
C
C
C
O4'
C1'
N9
DG
DG
DG
14
14
14
N
5
3.03
0.50
113.10
116.13
C
C
C
N7
C8
N9
DG
DG
DG
14
14
14
N
5
2.71
0.30
108.30
111.01
C
C
C
O4'
C1'
N1
DC
DC
DC
16
16
16
N
5
-4.94
0.80
105.90
100.96
D
D
D
O4'
C1'
C2'
DG
DG
DG
17
17
17
N
5
3.44
0.50
113.10
116.54
D
D
D
N7
C8
N9
DG
DG
DG
17
17
17
N
5
-5.16
0.70
102.20
97.04
D
D
D
C4'
C3'
C2'
DC
DC
DC
19
19
19
N
5
2.24
0.30
108.30
110.54
D
D
D
O4'
C1'
N1
DC
DC
DC
19
19
19
N
5
-5.61
0.80
105.90
100.29
D
D
D
O4'
C1'
C2'
DG
DG
DG
20
20
20
N
5
2.53
0.30
108.30
110.83
D
D
D
O4'
C1'
N9
DG
DG
DG
20
20
20
N
5
3.22
0.50
113.10
116.32
D
D
D
N7
C8
N9
DG
DG
DG
20
20
20
N
1
C
C
C5
C7
DT
DT
15
15
0.039
0.006
1.496
1.535
N
1
D
D
C5
C7
DT
DT
21
21
0.043
0.006
1.496
1.539
N
2
C
C
C5
C7
DT
DT
15
15
0.042
0.006
1.496
1.538
N
3
C
C
C5
C7
DT
DT
15
15
0.038
0.006
1.496
1.534
N
4
C
C
C5
C7
DT
DT
15
15
0.036
0.006
1.496
1.532
N
4
D
D
C5
C7
DT
DT
21
21
0.036
0.006
1.496
1.532
N
5
C
C
C5
C7
DT
DT
15
15
0.040
0.006
1.496
1.536
N
5
D
D
C5
C7
DT
DT
21
21
0.037
0.006
1.496
1.533
N
5
A
NCY
3
-98.73
-61.43
5
A
NCY
7
-90.57
-62.43
model building
X-PLOR
refinement
X-PLOR
phasing
X-PLOR
TRIOSTIN A
SEQUENCE SPECIFICITY OF QUINOXALINE ANTIBIOTICS. 1. SOLUTION STRUCTURE OF A 1:1 COMPLEX BETWEEN TRIOSTIN A AND [D(GACGTC)]2 AND COMPARISON WITH THE SOLUTION STRUCTURE OF THE [N-MECYS3, N-MECYS7]TANDEM-[D(GATATC)]2 COMPLEX
1
N
N
2
N
N
2
N
N
3
N
N
3
N
N
disulf
2.021
A
NCY
3
A
SG
NCY
3
1_555
A
NCY
7
A
SG
NCY
7
1_555
covale
1.329
A
QUI
0
D
C
QUI
1_555
A
DSN
1
A
N
DSN
1
1_555
covale
1.305
A
DSN
1
A
C
DSN
1
1_555
A
ALA
2
A
N
ALA
2
1_555
covale
1.331
A
DSN
1
A
OG
DSN
1
1_555
A
MVA
8
A
C
MVA
8
1_555
covale
1.323
A
ALA
2
A
C
ALA
2
1_555
A
NCY
3
A
N
NCY
3
1_555
covale
1.329
A
NCY
3
A
C
NCY
3
1_555
A
MVA
4
A
N
MVA
4
1_555
covale
1.333
A
MVA
4
A
C
MVA
4
1_555
A
DSN
5
A
OG
DSN
5
1_555
covale
1.303
A
DSN
5
A
C
DSN
5
1_555
A
ALA
6
A
N
ALA
6
1_555
covale
1.327
A
DSN
5
A
N
DSN
5
1_555
A
QUI
9
E
C
QUI
1_555
covale
1.326
A
ALA
6
A
C
ALA
6
1_555
A
NCY
7
A
N
NCY
7
1_555
covale
1.327
A
NCY
7
A
C
NCY
7
1_555
A
MVA
8
A
N
MVA
8
1_555
hydrog
DG-DT MISPAIR
C
DG
11
B
O6
DG
1
1_555
D
DT
21
C
N3
DT
5
1_555
hydrog
WATSON-CRICK
C
DG
11
B
N1
DG
1
1_555
D
DC
22
C
N3
DC
6
1_555
hydrog
WATSON-CRICK
C
DG
11
B
N2
DG
1
1_555
D
DC
22
C
O2
DC
6
1_555
hydrog
WATSON-CRICK
C
DG
11
B
O6
DG
1
1_555
D
DC
22
C
N4
DC
6
1_555
hydrog
WATSON-CRICK
C
DA
12
B
N1
DA
2
1_555
D
DT
21
C
N3
DT
5
1_555
hydrog
WATSON-CRICK
C
DA
12
B
N6
DA
2
1_555
D
DT
21
C
O4
DT
5
1_555
hydrog
WATSON-CRICK
C
DC
13
B
N3
DC
3
1_555
D
DG
20
C
N1
DG
4
1_555
hydrog
WATSON-CRICK
C
DC
13
B
N4
DC
3
1_555
D
DG
20
C
O6
DG
4
1_555
hydrog
WATSON-CRICK
C
DC
13
B
O2
DC
3
1_555
D
DG
20
C
N2
DG
4
1_555
hydrog
WATSON-CRICK
C
DG
14
B
N1
DG
4
1_555
D
DC
19
C
N3
DC
3
1_555
hydrog
WATSON-CRICK
C
DG
14
B
N2
DG
4
1_555
D
DC
19
C
O2
DC
3
1_555
hydrog
WATSON-CRICK
C
DG
14
B
O6
DG
4
1_555
D
DC
19
C
N4
DC
3
1_555
hydrog
DT-DG MISPAIR
C
DT
15
B
N3
DT
5
1_555
D
DG
17
C
O6
DG
1
1_555
hydrog
WATSON-CRICK
C
DT
15
B
N3
DT
5
1_555
D
DA
18
C
N1
DA
2
1_555
hydrog
WATSON-CRICK
C
DT
15
B
O4
DT
5
1_555
D
DA
18
C
N6
DA
2
1_555
hydrog
WATSON-CRICK
C
DC
16
B
N3
DC
6
1_555
D
DG
17
C
N1
DG
1
1_555
hydrog
WATSON-CRICK
C
DC
16
B
N4
DC
6
1_555
D
DG
17
C
O6
DG
1
1_555
hydrog
WATSON-CRICK
C
DC
16
B
O2
DC
6
1_555
D
DG
17
C
N2
DG
1
1_555
DNA/ANTIBIOTIC
BISINTERCALATOR, DEPSIPEPTIDE, QUINOXALINE, ANTIBIOTIC, ANTITUMOR, DNA-ANTIBIOTIC COMPLEX
NOR01129
NOR
1
NOR01129
185D
PDB
2
185D
1
8
185D
1
8
NOR01129
A
1
1
8
1
6
185D
11
16
185D
C
2
1
6
1
6
185D
17
22
185D
D
2
1
6
BINDING SITE FOR CHAIN A OF TRIOSTIN A
Software
8
C
DA
12
B
DA
2
8
1_555
C
DC
13
B
DC
3
8
1_555
C
DG
14
B
DG
4
8
1_555
C
DT
15
B
DT
5
8
1_555
D
DA
18
C
DA
2
8
1_555
D
DC
19
C
DC
3
8
1_555
D
DG
20
C
DG
4
8
1_555
D
DT
21
C
DT
5
8
1_555
1
P 1